Loading clinical trials...

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00979251

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir mo...

Lead sponsor: Adamas Pharmaceuticals, Inc.•16 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITING

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

NCT01386424 · Zika, Influenza

RECRUITINGPhase 1

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318 · Influenza

RECRUITINGPhase 2

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

NCT05648448 · Influenza, Influenza, Human

RECRUITINGPhase 1/2

Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

NCT07291635 · Influenza

RECRUITINGPhase 2

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

NCT06599658 · COVID 19, Influenza, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 14, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment2

Start dateSep 2009

Last updatedApr 14, 2014

Condition

Influenza

Locations shown

Adamas Investigational Site

San Francisco, California

Adamas Investigational Site

San Francisco, California

Adamas Investigational Site

San Francisco, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 14, 2014Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

Trial snapshot

Condition

Locations shown

For caregivers